Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that castration-resistant prostate cancers resistant to CYP17A1 inhibitors may still depend on steroids and could respond to therapies targeting de novo intratumoral steroid synthesis.

In this study, a treatment regimen combining cyproterone acetate and ethinyl estradiol significantly improved acne and seborrhoea in most women after three months, but had varied effects on hirsutism and alopecia.

Minoxidil works better for female hair loss, but cyproterone reduces scalp oiliness and causes menstrual issues.

Cyproterone Acetate effectively treats androgen-related conditions and is used in prostate cancer therapy and hormone therapy for transgender women.

This study found that all four treatments—flutamide, finasteride, ketoconazole, and EE-CPA—significantly reduced hirsutism, but EE-CPA and flutamide appeared most effective, with varying effects on androgen levels and side-effect profiles.

In this study, cyproterone acetate at 2 mg daily was found to be as effective as higher doses in reducing hair growth for hirsute women over 12 months.

CYP11A1 is crucial for skin health and disease by producing important steroids.

This study found that high doses of cyproterone acetate were associated with an increased risk of meningioma, especially with exposure longer than one year.

This study found that treatment with cyproterone acetate and ethinyl oestradiol increased hair density in women with diffuse androgen-dependent alopecia, particularly when serum ferritin levels were above 40 μg/l.

This review found that adding cyproterone acetate to estradiol showed a subjective improvement in hirsutism versus placebo, but comparisons with other therapies revealed no clinical differences.

This study found that the oral contraceptive containing drospirenone (EE/DRSP) was as effective as EE/CPA in reducing acne lesions, sebum production, and hair growth in women with acne.

This study found that both cyproterone acetate and spironolactone effectively reduced hair diameter and plasma testosterone levels in hirsute women, with no significant differences between the two treatments.

In this study, cyproterone acetate combined with estradiol dramatically improved hirsutism symptoms and significantly reduced plasma testosterone and androstenedione levels in patients over periods of up to three years.

This study found a strong dose-related increase in the risk of intracranial meningiomas associated with high doses of cyproterone acetate, with some reduction in risk after stopping the treatment.

This study identified that the enzyme CYP2B12 is skin-specific and likely plays a role in the metabolism of arachidonic acid, a key component in lipid signaling within sebaceous glands.

This study found that cyproterone acetate, given with ethinyl oestradiol, significantly reduced hirsutism in women after 12 months, although improvements reversed once cyproterone acetate was stopped.

This study found that while cyproterone acetate, finasteride, and spironolactone had similar short-term effects in treating idiopathic hirsutism, spironolactone provided more lasting benefits one year after treatment.

This study found that liarozole is more effective than cyproterone acetate for improving PSA response and survival in metastatic prostate cancer after first-line endocrine therapy, while maintaining quality of life.

This review examines the role of steroidal inhibitors in treating prostatic diseases but presents no new clinical results.

This review discusses the role of CYP gene polymorphisms in exacerbating hyperandrogenism in women with PCOS and reports no clinical results; further validation of this hypothesis is needed.

In this study, both cyproterone acetate-estrogen combination (Diane®) and finasteride were effective in reducing hirsutism, but Diane® showed greater long-term efficacy and cost-effectiveness.

This study found that both a high dose of CPA and GnRHa are effective for treating hirsutism in hyperandrogenic women, but GnRHa with add-back therapy may lead to a longer remission period.

This study found that combining cyproterone acetate with testosterone enanthate was highly effective in suppressing spermatogenesis, suggesting potential as a reversible male contraceptive method.

This review examines androgen status in male and female obesity and its influence on the metabolic syndrome, but reports no new clinical results.

This study found that the combination of cyproterone acetate and ethinyl estradiol improved hirsutism and acne in women, with SH 8.1041 showing significant results and both treatments being generally well-tolerated.

The study found that cyproterone acetate-loaded nanostructured lipid carriers, particularly those with a 300 nm diameter, improved skin penetration and targeted hair follicles more effectively than free cyproterone acetate.

This study suggests that although the G972R variant of the IRS1 gene might increase AA excess risk in heterozygous carriers with CYP21 mutations, both variations play a limited role in PCOS development.

This study found that both finasteride and a regimen of cyproterone acetate plus ethinyl estradiol effectively reduced hirsutism in women, with similar results despite differing hormonal effects.

In this study, cyproterone acetate with ethinyl estradiol effectively treated acne, hirsutism, and alopecia in women, with the highest success in acne and rare side effects similar to estrogen contraceptives.

In this retrospective study, cyproterone acetate treatment in late-pubertal trans-girls was found to be generally safe and led to mild feminizing effects, with more rapid feminization occurring when combined with estrogens.